Dr. Hartmut Krafft gained his master degree and PhD at the German Cancer Research Centre Heidelberg, Department of Cell Biology and Immunology. As Post-Doc he worked at the German Cancer Research Centre and the European Molecular Biology Laboratory in Heidelberg as well as for the Institute of Pathology at the University Hospital in Regensburg. At the Paul-Ehrlich-Institut he was responsible for marketing authorization, batch release and regulatory affairs of immunoglobulins, sera and monoclonal antibodies.
Currently he is working as Head of the section Clinical Trials at the PEI. He is Chair of the Heads of Medicines Agencies (MA) Clinical Trials Facilitation Group (CTFG) and Coordinator of the Voluntary Harmonisation Procedure (VHP).